BioCardia (BCDA) Cash from Financing Activities (2010 - 2026)

BioCardia (BCDA) has reported Cash from Financing Activities for 13 consecutive years, with $4.9 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash from Financing Activities rose 191.55% year-over-year to $4.9 million in Q2 2026; TTM through Jun 2026 was $10.7 million, a 36.0% increase from a year earlier, with the FY2025 full-year figure at $7.6 million, down 17.38% from the prior year.
• Cash from Financing Activities was $4.9 million for Q2 2026 at BioCardia, up from $117000.0 in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $6.1 million in Q3 2024 and troughed at -$288000.0 in Q4 2025.
• A 5-year average of $1.8 million and a median of $1.4 million in 2022 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities slumped 179.45% in 2023 and surged 10655.17% in 2024, its largest moves.
• Over 5 years, Cash from Financing Activities stood at $3.7 million in 2022, then sank by 69.72% to $1.1 million in 2023, then plunged by 111.17% to -$125000.0 in 2024, then slumped by 130.4% to -$288000.0 in 2025, then surged by 1801.74% to $4.9 million in 2026.
• The last three Cash from Financing Activities figures came in at $4.9 million (Q2 2026), $117000.0 (Q1 2026), and -$288000.0 (Q4 2025), per Business Quant data.